APA (7th ed.) Citation

AJ, I., LB, C., S, M., E, B., C, C., G, S., . . . D, M. (2020). Ruxolitinib for tocilizumab-refractory severe COVID-19 infection. British journal of haematology, 190(4), e198. https://doi.org/10.1111/bjh.16979

Chicago Style (17th ed.) Citation

AJ, Innes, Cook LB, Marks S, Bataillard E, Crossette-Thambiah C, Sivasubramaniam G, Apperley J, and Milojkovic D. "Ruxolitinib for Tocilizumab-refractory Severe COVID-19 Infection." British Journal of Haematology 190, no. 4 (2020): e198. https://doi.org/10.1111/bjh.16979.

MLA (9th ed.) Citation

AJ, Innes, et al. "Ruxolitinib for Tocilizumab-refractory Severe COVID-19 Infection." British Journal of Haematology, vol. 190, no. 4, 2020, p. e198, https://doi.org/10.1111/bjh.16979.